Brief: Lipella Pharmaceuticals Announces US FDA Clearance Of IND For LP-410 For Oral Graft-Versus-Host Disease
05/03/2024 13:38
March 5 (Reuters) - Lipella Pharmaceuticals Inc
LIPO.O :
* LIPELLA PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR
LP-410 FOR ORAL GRAFT-VERSUS-HOST DISEASE, ADVANCING CLINICAL
PIPELINE
Source text for Eikon: ID:nGNX8dmY5c
Further company coverage: LIPO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipella Pharmaceuticals
See all newsBrief: Lipella Pharmaceuticals Says Bankruptcy Court Approves Sale And Asset Purchase Agreement On June 4
Brief: Lipella Pharmaceuticals Inc. Files Voluntary Petitions For Relief Under Chapter 11
Brief: Lipella Pharmaceuticals Announces Positive Final Results From Phase 2a Study Of LP-10 In Oral Lichen Planus
Brief: Lipella Pharmaceuticals Announces Delisting From Nasdaq Capital Market
U.S. STOCKS ON THE MOVE-Marriott International, Coty, Carlyle Group